The agreement follows on from an evaluation by AstraZeneca, which is capped at $81 billion, which began in September 2012 of Starpharma’s delivery technology, and will see the application of Starpharma’s technology to a cancer drug, from AstraZeneca’s pipeline.
AstraZeneca will provide funding for a preclinical stage cancer research program to be conducted jointly.
Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses.
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Partnering Agreements with AstraZeneca 2009-2014
Report: Practical Guide to Finding Partners
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity